Distinguished in Neuroblastoma

Birgit Geoerger

Gustave Roussy
Villejuif, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Neuroblastoma
Gustave Roussy
Villejuif, FR 
OverviewLocationsClinical Research

Overview

Birgit Geoerger practices in Villejuif, France. Ms. Geoerger is rated as a Distinguished expert by MediFind in the treatment of Neuroblastoma. Her top areas of expertise are Rhabdomyosarcoma, Embryonal Tumor with Multilayered Rosettes, Adult Soft Tissue Sarcoma, and Gliomatosis Cerebri.

Her clinical research consists of co-authoring 155 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 20 articles and participated in 2 clinical trials in the study of Neuroblastoma.

Gender
Female

Locations

Gustave Roussy
Villejuif, 94805, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Enrollment Status: Recruiting
Publish Date: January 10, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)
A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)
Enrollment Status: Completed
Publish Date: October 07, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Irinotecan, Temozolomide
Study Phase: Phase 1/Phase 2
Phase I Clinical Trial of Rapamycin and Irinotecan in Pediatric Patients With Refractory Solid Tumors
Phase I Clinical Trial of Rapamycin and Irinotecan in Pediatric Patients With Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: September 22, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Multicentre, Open-Label, Dose-Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Patients With Recurrent or Refractory Solid Tumours
A Phase 1, Multicentre, Open-Label, Dose-Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Patients With Recurrent or Refractory Solid Tumours
Enrollment Status: Terminated
Publish Date: July 16, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors
A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors
Enrollment Status: Active_not_recruiting
Publish Date: April 23, 2025
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 1/Phase 2
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Enrollment Status: Completed
Publish Date: October 03, 2024
Intervention Type: Drug
Study Drug: Tazemetostat
Study Phase: Phase 1
Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma
Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma
Enrollment Status: Completed
Publish Date: November 18, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

155 Total Publications

Fighting sarcomas at the root: The role of mesenchymal stem cells in sarcomagenesis.
Fighting sarcomas at the root: The role of mesenchymal stem cells in sarcomagenesis.
Journal: European journal of cancer (Oxford, England : 1990)
Published: June 06, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Geoerger's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 7 Advanced Conditions
View All 27 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile